Poging GOUD - Vrij
TCS is treading in rough waters
Mint Chennai
|July 14, 2025
A crucial guage Value of TCS's deal wins was back to sub-$10 billion range in Q1FY26 after a robust show in Q4FY25.
A weaker-than-anticipated June quarter (Q1 FY26) result of Tata Consultancy Services Ltd has raised concerns about a delay in revenue revival. It has got investors wondering if the earnings downgrade cycle for the sector has bottomed out or if there is more pain ahead. Sequential constant-currency (CC) revenue fell 3.3% versus the Bloomberg consensus estimate of a 1.4% decline in Q1. The miss was driven by the ramp-down of the BSNL project and a sequential CC revenue drop in international markets.
Clients remain cautious, with cost optimization, vendor consolidation, and efficiency-led technology transformation as priorities, the management said. Discretionary IT spending remains under pressure. However, demand for GenAI, cloud adoption, and platform modernization was firm. Banking and financial services saw pockets of softness, especially in US insurance. Consumer-facing sectors, particularly retail and automotive, were hit by project deferrals and funding delays due to macro headwinds and delayed decision-making in markets like North America.
Dit verhaal komt uit de July 14, 2025-editie van Mint Chennai.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint Chennai
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
